Overview
- HHS will wind down 22 BARDA contracts worth $500 million that funded mRNA vaccine development for respiratory viruses
- The canceled projects led by Pfizer, Moderna, Sanofi Pasteur and other firms targeted vaccines against COVID-19, flu and H5N1
- HHS said other mRNA applications remain unaffected and approved mRNA vaccines for COVID-19 and RSV will continue in use
- Experts including Rick Bright and Mike Osterholm warned that ending mRNA research now could weaken future pandemic preparedness
- Kennedy affirmed support for safe, effective vaccines and announced a shift toward whole-virus and novel vaccine platforms with work on a potential universal vaccine